Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients

  • Published : 2014.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The current standard treatment for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) is rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). A significant number of patients were not treated with recommended dose of rituximab due to limited financial resources in Malaysia. This study evaluates the efficacy of R-CHOP like chemotherapy in Malaysian patients with DLBCL. Materials and Methods: The study comprised a retrospective analysis of patients with DLBCL treated at a single centre. The outcome was compared with patients who were treated with R-CHOP like and CHOP like chemotherapy. Patients who were treated with lower dose of rituximab was subanalysed for outcome. Results: A total of 86 patients who had CHOP-like chemotherapy were included. Only 39 (45%) patients had rituximab and only 12 (29%) patients had the recommended dose. The overall response (OR) and complete response (CR) rates were 88% and 81% respectively. There was no significant difference in OR and CR in patients who had rituximab and those without rituxmab. Those with International Prognostic Index (IPI) score of ${\leq}2$ had significant higher CR rate, progression free survival (PFS) and overall survival (p<0.001). Conclusions: The lack of significant improvement in CR and DFS in our patients may be due to an inadequate dose of rituximab.

Keywords

References

  1. Armitage JO (2012). My treatment approach to patients with Diffuse Large B cell Lymphoma. Mayo Clin Pro, 87, 161-71. https://doi.org/10.1016/j.mayocp.2011.11.007
  2. Blay J, Gomez F, Sebban C, et al (1998). The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood, 92, 3562-8.
  3. Castillo JJ, Sinclair N, Beltran BE, et al (2013). Similar outcomes in Asian and Western patients with diffuse large B cell lymphoma treated witn R-CHOP. Leukemia res, 37, 386-91. https://doi.org/10.1016/j.leukres.2013.01.002
  4. Chihara D, Ito H, Matsuda T, et al (2013). Differences in incidence and trends of hematological malignancies in Japan and United States. Br J Haematol, 164, 536-45.
  5. Coiffer B, Lepage E, Briere J, et al (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. New Eng J Med, 346, 235-42. https://doi.org/10.1056/NEJMoa011795
  6. Feugier P, Van Hoof A, Sebban C, et al (2005). Long term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma, a study by European Groupe D'Estude des Lymphomes des L'Adulte (GELA). J Clin Oncol, 23, 4117-26. https://doi.org/10.1200/JCO.2005.09.131
  7. Fu K, Weisinburger DD, Choi WW, et al (2008). Addition of rituximab to standard chemotherapy improves the survival of germinal centre B-cell like and non germinal centre B-cell like subtypes of diffuse large B cell lymphoma. J Clin Oncol, 26, 4587-94. https://doi.org/10.1200/JCO.2007.15.9277
  8. Huh J (2012). Epidemiologic overview of malignant lymphoma. Korean J Hematol, 47, 92-104. https://doi.org/10.5045/kjh.2012.47.2.92
  9. Intragumthornchai T, BunwarosateU, Siritanaratkul N, et al (2013). Inferior progression free survival for Thai patients with diffuse largeB-cell lymphoma treated under Universal Coverage Scheme, the impact of rituximab inaccessibility. Leuk Lymp, 54, 83-9. https://doi.org/10.3109/10428194.2012.698739
  10. Lenz G, Wright DH, Dave SS, et al (2007). Gene expression signatures predict overall survival in diffuse large B cell lymphoma treated with rituximab and CHOP-like chemotherapy. Blood, 110, 109.
  11. Li JM, Wang L, Shen Y, et al (2007). Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol, 86, 639-45. https://doi.org/10.1007/s00277-007-0320-8
  12. Li Y, Yimamu M, Wang X, et al (2014). Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B-cell lymphoma cells with high Bcl-2 expression. Int J Hematol, 99, 79-86. https://doi.org/10.1007/s12185-013-1472-z
  13. Ngo L, Hee SW, Lim LC, et al (2008). Prognostic factors in patients with diffuse large B cell lymphoma: before and after introduction of rituximab. Leukemia Lymphoma, 49, 462-9. https://doi.org/10.1080/10428190701809156
  14. Nishimori H, Matsua K, Maeda Y, et al (2009). The effect of adding rituximab to CHOP based therapy on clinical outcomes for Japanese patients with diffuse large b cell lymphoma: a propensity score matching analysis. Int J Hematol, 89, 326-31. https://doi.org/10.1007/s12185-009-0259-8
  15. Park YH, Lee JJ, Ryu MH, et al (2006). Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Int J Haem, 85, 257-2.
  16. Pfreundschuh M, Trumper L, Ostenberg A, et al (2006). CHOP like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B cell lymphoma: a randomized controlled trial by the MabThera international trial (MInT) group. Lancet Oncol, 7, 379-91. https://doi.org/10.1016/S1470-2045(06)70664-7
  17. Rosenwald A, Wright G, Chan WC, et al (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. New Eng J Med, 346, 1937-47. https://doi.org/10.1056/NEJMoa012914
  18. Sehn LH, Donalson J, Chhanabhai M, et al (2005), Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol, 23, 5027-33. https://doi.org/10.1200/JCO.2005.09.137
  19. Seiki R, Ohshima K, Nagafuji K, et al (2010). Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 91, 258-66. https://doi.org/10.1007/s12185-009-0475-2
  20. Shia AKH, Gan GG, Jairaman S, Peh SC, et al (2005). High frequency of germinal centre derivation n diffuse large B cell lymphoma from Asian patients. J Clin Pathol, 58, 962-7. https://doi.org/10.1136/jcp.2004.022624
  21. Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al ( 2007). The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res, 31, 1579-83. https://doi.org/10.1016/j.leukres.2007.03.017
  22. Teo MC, Soo KC (2013) Cancer trends and incidences in Singapore. Jpn J Clin Oncol, 43, 219-24. https://doi.org/10.1093/jjco/hys230
  23. Visco C, Tzankov A, Xu-Manoette ZY, et al (2013). Patients with diffuse large B cell lymphoma of germinal centre with BCL2 translocation have poor outcome; irrespective of MYC status: a report from an international DLBCL rituximab- CHOP consortium program study. Haematologica, 98, 255-63. https://doi.org/10.3324/haematol.2012.066209
  24. Vose JM, Link BK, Grossbard ML, et al (2001). Phase II study of rituximab in combination of CHOP chemotherapy in patients with previously, untreated aggressive non-Hodgkin lymphoma. J Clin Oncol, 19, 387-97.

Cited by

  1. FNC, a Novel Nucleoside Analogue, Blocks Invasion of Aggressive Non-Hodgkin Lymphoma Cell Lines Via Inhibition of the Wnt/β-Catenin Signaling Pathway vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6829
  2. Quality of life amongst lymphoma survivors in a developing country vol.24, pp.12, 2016, https://doi.org/10.1007/s00520-016-3364-2